AIkido Pharma Confirms Receipt Of Unsolicited Offer For $8/Share In Cash

8/10/22 8:35:56 AM ET

Specialty Chemicals

Consumer Discretionary

Get the next $AIKI alert in real time by email

AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash.

The Company's Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all AIkido shareholders. The Company will respond in due course.

There is no need for shareholders to take any action at this time.

Get the next $AIKI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AIKI

Date	Price Target	Rating	Analyst
10/11/2021	$2.00	Buy	HC Wainwright & Co.

More analyst ratings

AIkido Pharma Inc. Appoints New Director, Soo Yu
New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company. Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity. The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule. Further, Ms. Yu's background broadens t
6/10/22 4:15:00 PM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching
NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public. AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad
9/14/21 9:22:00 AM ET
$AIKI
$DATS
Specialty Chemicals
Consumer Discretionary
Telecommunications Equipment
Telecommunications
AIkido Pharma Provides Business Update
NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our
4/5/21 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary

Dominari Holdings Provides Update on Share Repurchase Program
NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part
12/28/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)
NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C
12/22/22 8:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary
AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes
Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita
11/28/22 9:00:00 AM ET
$AIKI
Specialty Chemicals
Consumer Discretionary

AIkido Pharma Confirms Receipt Of Unsolicited Offer For $8/Share In Cash

Chat with this insight

Recent Analyst Ratings for $AIKI

$AIKI Market Insights

Live Market Insights

$5 Million Bet On SoFi Technologies? Check Out These 5 Penny Stocks Insiders Are Buying

HC Wainwright & Co. Maintains Buy on AIkido Pharma, Lowers Price Target to $16

Alkido Pharma Says On Oct. 17, Kyle Wool Entered Into Amended And Restated Services Agreement With Co.'s Unit

$AIKI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by AIkido Pharma Inc.

SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

$AIKI Leadership Updates

Live Leadership Updates

$AIKI Press Releases

Fastest customizable press release news feed in the world

AIkido Pharma Inc. Appoints New Director, Soo Yu

AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

AIkido Pharma Provides Business Update

Dominari Holdings Provides Update on Share Repurchase Program

AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

$AIKI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. initiated coverage on AIkido Pharma with a new price target

$AIKI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)

$AIKI SEC Filings

AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by AIkido Pharma Inc.

$AIKI Financials

Live finance-specific insights

$AIKI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

Recent Analyst Ratings for
$AIKI

$AIKI
Market Insights

$AIKI
Large Ownership Changes

$AIKI
Leadership Updates

$AIKI
Press Releases

$AIKI
Analyst Ratings

$AIKI
Insider Trading

$AIKI
SEC Filings

$AIKI
Financials

$AIKI
Insider Purchases